High levels of RSV cases highlight need for greater vaccine awareness

Respiratory syncytial virus (RSV) cases have reached alarming levels across the United States, with several states reporting “very high” activity according to CDC wastewater testing. This surge underscores the critical need to raise awareness about RSV prevention, especially as we navigate only the second RSV season with vaccines available. Despite the introduction of effective preventive measures, many families remain uninformed about their options, leaving infants—the most vulnerable population—at risk. Public health authorities and researchers are working to collect real-world data on the safety, effectiveness, and uptake of RSV prophylaxis. Recent studies offer important insights into the current landscape of RSV prevention, highlighting successes and identifying opportunities for improvement. The current landscape of RSV prevention Two primary products are recommended to protect infants against RSV. The maternal RSV vaccine (RSVPreF) is administered during pregnancy, transferring protective antibodies to the fetus. This passive immunization is designed to protect newborns from birth. Alternatively, nirsevimab, a monoclonal...